Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brigatinib + binimetinib
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Brigatinib + binimetinib is an investigational **oral combination therapy consisting of brigatinib, an anaplastic lymphoma kinase (ALK) inhibitor, and binimetinib, a selective inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)**. Brigatinib blocks ALK-mediated and mutant epidermal growth factor receptor (EGFR) signaling, inhibiting tumor cell proliferation and survival in ALK-positive cancers. Binimetinib targets MEK1/2 to interrupt the RAS/RAF/MEK/ERK signaling cascade and reduce tumor cell proliferation. The combination is under investigation for unresectable or metastatic non-small cell lung cancer (NSCLC), especially for ALK-positive or resistant cases, aiming to address resistance mechanisms to ALK inhibition.
- Other names
- brigatinib and binimetinib
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on brigatinib + binimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brigatinib + binimetinib.